# AstraZeneca Plc Trastuzumab deruxtecan demonstrated clinically

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-trastuzumab-deruxtecan-demonstrated-clinically/412774233
- Published: 2019-05-08T07:45:02+01:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-
line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan(
DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine
was evaluated in patients with HER2-positive, unresectable and/or metastatic breast
cancer previously treated with trastuzumab emtansine.

The response rate in DESTINY-Breast01, as assessed by an independent review committee,
confirms in a heavily-pretreated, global patient population the unprecedented clinical
activity in the recently-published Phase I trial. The safety and tolerability profile
of trastuzumab deruxtecan was also consistent with previous experience. These results
are expected to support planned global regulatory submissions, including a Biologics
License Application with the US Food and Drug Administration (FDA) anticipated in
the second half of 2019.

DESTINY-Breast01 is a pivotal Phase II, open-label, global, multicentre, two-part
trial of trastuzumab deruxtecan. The optimal dose of 5.4mg/kg was previously identified
in part one of the trial. Today’s results from part two evaluated the efficacy and
safety of that dose in patients who have failed or discontinued previous treatment
with trastuzumab emtansine.

> **José Baselga, Executive Vice President, R&D Oncology, said:** “We are encouraged
> to see positive data from trastuzumab deruxtecan, with the DESTINY-Breast01 trial
> now reinforcing what earlier data have shown. We believe this antibody drug conjugate
> has the potential to redefine the treatment of patients with HER2-expressing cancers,
> and we are eager to bring it as quickly as possible to patients with refractory
> HER2-positive breast cancer who continue to have high unmet medical need.”
> **Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research
> and Development, Daiichi Sankyo, said**: “These results confirm our commitment
> to pursue accelerated regulatory pathways in HER2-positive metastatic breast cancer
> with trastuzumab deruxtecan. We are more dedicated than ever to our comprehensive
> and ambitious development strategy evaluating the potential across a spectrum 
> of HER2-expressing cancers including breast, gastric, lung and colorectal.”

Trastuzumab deruxtecan has been granted US FDA Breakthrough Therapy Designation 
and Fast Track Designation for HER2-positive patients in the advanced or refractory
breast cancer setting. A recent publication in The Lancet Oncology reported long-
term Phase I safety and preliminary efficacy results in HER2-positive metastatic
breast cancer. This potential new medicine is currently in development for the treatment
of multiple HER2-expressing cancers, including in patients with HER2-low expression.

AstraZeneca and Daiichi Sankyo plan to present the data from DESTINY-Breast01 at
a forthcoming medical meeting.

Share on:
